Literature DB >> 12821621

Antiphospholipid syndrome: an overview.

John G Hanly1.   

Abstract

Antiphospholipid antibodies are a heterogeneous group of autoantibodies that are detected by immunoassays and functional coagulation tests. The antigenic targets are negatively charged phospholipids and serum phospholipid-binding proteins. The latter antibodies are frequently associated with thrombosis, fetal loss and other clinical manifestations of the antiphospholipid syndrome. These antibodies are felt to be etiologically important in the syndrome, although the precise pathogenic mechanisms are still being determined. Proposed mechanisms include antibody-mediated interference with coagulation homeostasis, activation of platelets and endothelial cells and a T-cell immune response to serum phospholipid-binding proteins. The mainstay of therapy is anticoagulation, whereas immunosuppression is ineffective.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821621      PMCID: PMC161613     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  98 in total

1.  Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.

Authors:  D Alarcón-Segovia; M Delezé; C V Oria; J Sánchez-Guerrero; L Gómez-Pacheco; J Cabiedes; L Fernández; S Ponce de León
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

2.  Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders.

Authors:  E N Harris; A E Gharavi; G D Wasley; G R Hughes
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

3.  Anti-prothrombin antibodies and the lupus anticoagulant.

Authors:  R A Fleck; S I Rapaport; L V Rao
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

4.  Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation.

Authors:  J Nimpf; H Wurm; G M Kostner
Journal:  Atherosclerosis       Date:  1987-02       Impact factor: 5.162

5.  Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder.

Authors:  C G Mackworth-Young; S Loizou; M J Walport
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

6.  In vitro activation of the contact activation system (Hageman factor system) in plasma by acidic phospholipids and the inhibitory effect of beta 2-glycoprotein I on this activation.

Authors:  I Schousboe
Journal:  Int J Biochem       Date:  1988

Review 7.  Endothelial cell procoagulant properties and the host response.

Authors:  P P Nawroth; D M Stern
Journal:  Semin Thromb Hemost       Date:  1987-10       Impact factor: 4.180

8.  The "primary" antiphospholipid syndrome: major clinical and serological features.

Authors:  R A Asherson; M A Khamashta; J Ordi-Ros; R H Derksen; S J Machin; J Barquinero; H H Outt; E N Harris; M Vilardell-Torres; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

9.  Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I.

Authors:  J Nimpf; E M Bevers; P H Bomans; U Till; H Wurm; G M Kostner; R F Zwaal
Journal:  Biochim Biophys Acta       Date:  1986-10-29

10.  Primary antiphospholipid syndrome.

Authors:  D Alarcón-Segovia; J Sanchez-Guerrero
Journal:  J Rheumatol       Date:  1989-04       Impact factor: 4.666

View more
  25 in total

1.  Sudden sensorineural hearing loss in a patient with primary antiphospholipid syndrome.

Authors:  Levent Sinan Bir; Fatma Ozdemir Eşmeli; Fazil Necdet Ardiç
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 2.  Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons.

Authors:  Eyal Muscal; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

3.  Anti-phospholipid antibodies in serum from patients with Guillain-Barré syndrome.

Authors:  G Nakos; E Tziakou; L Maneta-Peyret; C Nassis; M E Lekka
Journal:  Intensive Care Med       Date:  2005-07-26       Impact factor: 17.440

Review 4.  Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.

Authors:  A M Lynch; J E Salmon
Journal:  Placenta       Date:  2010-04-27       Impact factor: 3.481

5.  Neurocognitive deficits and neuroimaging abnormalities are prevalent in children with lupus: clinical and research experiences at a US pediatric institution.

Authors:  E Muscal; D R Bloom; J V Hunter; B L Myones
Journal:  Lupus       Date:  2009-12-21       Impact factor: 2.911

6.  Activated protein C resistance and antiphospholipid antibodies in recurrent fetal loss: experience of a single referral center in northern iraq.

Authors:  Nasir A S Al-Allawi; Maida Y Shamdeen; Qais O Mohammed; Ahmed S Ahmed
Journal:  Indian J Hematol Blood Transfus       Date:  2014-02-23       Impact factor: 0.900

7.  Bilateral sudden hearing loss following habitual abortion: a case report and review of literature.

Authors:  Tuanfang Yin; Fengying Huang; Jihao Ren; Wei Liu; Xing Chen; Lihua Li; Dinghua Xie; Yongde Lu
Journal:  Int J Clin Exp Med       Date:  2013-09-01

Review 8.  [Antiphospholipid syndrome and retinal vein occlusion. Meta-analysis of Published Studies].

Authors:  M Rehak; M Müller; M Scholz; J Wiercinska; D Niederwieser; P Wiedemann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

Review 9.  Diagnosis and management of neuropsychiatric SLE.

Authors:  John G Hanly
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

Review 10.  Possible novel biomarkers of organ involvement in systemic lupus erythematosus.

Authors:  Dinglei Su; Rui Liu; Xia Li; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2014-03-06       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.